601 related articles for article (PubMed ID: 33052220)
21. Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Frost SH; Frayo SL; Miller BW; Orozco JJ; Booth GC; Hylarides MD; Lin Y; Green DJ; Gopal AK; Pagel JM; Bäck TA; Fisher DR; Press OW
PLoS One; 2015; 10(3):e0120561. PubMed ID: 25785845
[TBL] [Abstract][Full Text] [Related]
22. Preclinical evaluation of an
Kelly VJ; Wu ST; Gottumukkala V; Coelho R; Palmer K; Nair S; Erick T; Puri R; Ilovich O; Mukherjee P
Theranostics; 2020; 10(15):6946-6958. PubMed ID: 32550914
[No Abstract] [Full Text] [Related]
23. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
[TBL] [Abstract][Full Text] [Related]
24. Dual Radionuclide Theranostic Pretargeting.
Keinänen O; Brennan JM; Membreno R; Fung K; Gangangari K; Dayts EJ; Williams CJ; Zeglis BM
Mol Pharm; 2019 Oct; 16(10):4416-4421. PubMed ID: 31483993
[TBL] [Abstract][Full Text] [Related]
25. Development of a Theranostic Convergence Bioradiopharmaceutical for Immuno-PET Based Radioimmunotherapy of L1CAM in Cholangiocarcinoma Model.
Song IH; Jeong MS; Hong HJ; Shin JI; Park YS; Woo SK; Moon BS; Kim KI; Lee YJ; Kang JH; Lee TS
Clin Cancer Res; 2019 Oct; 25(20):6148-6159. PubMed ID: 31337646
[TBL] [Abstract][Full Text] [Related]
26. Pretargeted alpha emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid-biotin.
Yao Z; Zhang M; Garmestani K; Axworthy DB; Mallett RW; Fritzberg AR; Theodore LJ; Plascjak PS; Eckelman WC; Waldmann TA; Pastan I; Paik CH; Brechbiel MW; Carrasquillo JA
Clin Cancer Res; 2004 May; 10(9):3137-46. PubMed ID: 15131055
[TBL] [Abstract][Full Text] [Related]
27. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
29. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
30. Engineered Cells as a Test Platform for Radiohaptens in Pretargeted Imaging and Radioimmunotherapy Applications.
Dacek MM; Veach DR; Cheal SM; Carter LM; McDevitt MR; Punzalan B; Burnes Vargas D; Kubik TZ; Monette S; Santich BH; Yang G; Ouerfelli O; Kesner AL; Cheung NV; Scheinberg DA; Larson SM; Krebs S
Bioconjug Chem; 2021 Apr; 32(4):649-654. PubMed ID: 33819023
[TBL] [Abstract][Full Text] [Related]
31. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
32. Comparative Analysis of Bispecific Antibody and Streptavidin-Targeted Radioimmunotherapy for B-cell Cancers.
Green DJ; Frayo SL; Lin Y; Hamlin DK; Fisher DR; Frost SH; Kenoyer AL; Hylarides MD; Gopal AK; Gooley TA; Orozco JJ; Till BG; O'Steen S; Orcutt KD; Wilbur DS; Wittrup KD; Press OW
Cancer Res; 2016 Nov; 76(22):6669-6679. PubMed ID: 27590740
[TBL] [Abstract][Full Text] [Related]
33. Therapy of Myeloid Leukemia using Novel Bispecific Fusion Proteins Targeting CD45 and
Orozco JJ; Kenoyer AL; Lin Y; O'Steen S; Guel R; Nartea ME; Hernandez AH; Hylarides MD; Fisher DR; Balkin ER; Hamlin DK; Wilbur DS; Orcutt KD; Wittrup KD; Green DJ; Gopal AK; Till BG; Sandmaier B; Press OW; Pagel JM
Mol Cancer Ther; 2020 Dec; 19(12):2575-2584. PubMed ID: 33082277
[TBL] [Abstract][Full Text] [Related]
34. A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency.
Osl T; Schmidt A; Schwaiger M; Schottelius M; Wester HJ
Theranostics; 2020; 10(18):8264-8280. PubMed ID: 32724470
[TBL] [Abstract][Full Text] [Related]
35. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
[TBL] [Abstract][Full Text] [Related]
36. A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy.
Santich BH; Cheal SM; Ahmed M; McDevitt MR; Ouerfelli O; Yang G; Veach DR; Fung EK; Patel M; Burnes Vargas D; Malik AA; Guo HF; Zanzonico PB; Monette S; Michel AO; Rudin CM; Larson SM; Cheung NK
Clin Cancer Res; 2021 Jan; 27(2):532-541. PubMed ID: 32958698
[TBL] [Abstract][Full Text] [Related]
37. Radioimmunotherapy of A431 xenografted mice with pretargeted B3 antibody-streptavidin and (90)Y-labeled 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-biotin.
Yao Z; Zhang M; Axworthy DB; Wong KJ; Garmestani K; Park L; Park CW; Mallett RW; Theodore LJ; Yau EK; Waldmann TA; Brechbiel MW; Paik CH; Pastan I; Carrasquillo JA
Cancer Res; 2002 Oct; 62(20):5755-60. PubMed ID: 12384535
[TBL] [Abstract][Full Text] [Related]
38. Pretargeted radioimmunotherapy in tumored mice using an in vivo 212Pb/212Bi generator.
Su FM; Beaumier P; Axworthy D; Atcher R; Fritzberg A
Nucl Med Biol; 2005 Oct; 32(7):741-7. PubMed ID: 16243650
[TBL] [Abstract][Full Text] [Related]
39. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
[TBL] [Abstract][Full Text] [Related]
40. FZD10-targeted α-radioimmunotherapy with
Sudo H; Tsuji AB; Sugyo A; Harada Y; Nagayama S; Katagiri T; Nakamura Y; Higashi T
Cancer Sci; 2022 Feb; 113(2):721-732. PubMed ID: 34935247
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
